Mylan recalls anxiety medication due to ‘foreign material’

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Gustavofrazao)
(Image: Getty/Gustavofrazao)

Related tags: Recall, Mylan, Alprazolam

A voluntary recall of one lot of alprazolam tablets was announced by Mylan, after the potential presence of contaminant was discovered.

The adulterating substance, which was only identified as a ‘foreign substance’, led to a voluntary recall from the consumer level of one lot of alprazolam tablets 0.5mg.

The product is more commonly known by its branded name, Xanax, and is a treatment for anxiety and panic disorders.

Mylan noted in its release that any ‘clinical impact’ from the foreign material present is ‘expected to be a rare’, though it did indicate that there is a potential risk of infection that could not be ruled out.

The affected batch was distributed in the US between July and August 2019.

The company stated that it had notified distributors and customers of its decision to recall product.

Earlier this year​, Mylan had also issued a recall of two lots of levoleucovorin injection, after stability testing revealed that copper salts were present in the sterile injectable.

Related topics: Markets & Regulations, QA/QC, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more